[vc_row el_id=”mi-epembatikos”][vc_column][vc_row_inner el_class=”breadcrumbs”][vc_column_inner width=”1\/2″][vc_column_text][\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/2″][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”intro”][vc_column_inner][vc_single_image image=”668″][vc_column_text]<\/p>\n

Non-Invasive Prenatal Test (NIPT)<\/h1>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”description”][vc_column_inner width=”1\/2″][vc_column_text]<\/p>\n

GENOMEDICA, with the support of PERKIN ELMER, world leader in prenatal testing solutions, has installed and implements in its laboratories the unique Non-Invasive Prenatal Test (NIPT), VANADIS, which covers the wider geographical area of SE and Central Europe and Mediterranean and Middle East countries<\/h3>\n

[\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/2″][vc_raw_html]JTNDYSUyMGhyZWYlM0QlMjIlMkZwcm9kdWN0JTJGa2l0JTJGJTIyJTNFJTBBJTNDZGl2JTIwY2xhc3MlM0QlMjJidXR0b24tY3VzdG9tJTIwZC1mbGV4JTIwYnV5aXQlMjIlM0UlMEElM0NkaXYlMjBjbGFzcyUzRCUyMmIxJTIyJTNFQlVZJTIwSVQlM0MlMkZkaXYlM0UlMEElM0NkaXYlMjBjbGFzcyUzRCUyMmIyJTIyJTNFJTNDaW1nJTIwc3JjJTNEJTIyJTJGd3AtY29udGVudCUyRnVwbG9hZHMlMkYyMDIxJTJGMTAlMkZhcnJvdy13aGl0ZS5wbmclMjIlMjBhbHQlM0QlMjJhbHQtdGV4dCUyMiUyMCUyRiUzRSUzQyUyRmRpdiUzRSUwQSUzQyUyRmRpdiUzRSUyMCUzQyUyRmElM0U=[\/vc_raw_html][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”513″ img_size=”1634X427″ alignment=”center” css=”.vc_custom_1633947648139{margin-top: 4rem !important;margin-bottom: 5rem !important;}”][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_column_text el_class=”textred”]<\/p>\n

Vanadis NIPT is a targeted screening test which, by detecting fetal DNA from the mother’s blood, accurately calculates the possibility of the baby having Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome) and Trisomy 13 (Patau syndrome). These are the most common syndromes that occur spontaneously (ie without a specific predisposition) in pregnancies. The test can also detect the sex of the fetus.<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”info”][vc_column_inner][vc_column_text]<\/p>\n

ADVANTAGES<\/h1>\n

[\/vc_column_text][vc_column_text]<\/p>\n

With the new precision technology introduced by VANADIS, which relies on the imaging of individual fetal DNA molecules, more expectant mothers have access to reliable, fast and inexpensive non-invasive prenatal testing with a simple blood draw, as it achieves:<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”second-text”][vc_column_inner width=”1\/2″][vc_column_text]\u2022 Result in 5 to 10 working days
\n\u2022 Low cost
\n\u2022 Very high detection rates of syndromes DOWN, EDWARDS and PATAU (99.6% – 100%)
\n\u2022 The lowest rates of false positives compared to the competition (0.1% – 0.5%)
\n[\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/2″][vc_column_text]\u2022 The lowest percentage of unsuccessful (no-call) results (0.68%)
\n\u2022 High accuracy even in samples with low fetal DNA fraction (<2%)
\n\u2022 Certified for clinical diagnostic use as it bears the CE-IVD mark
\n\u2022 Developed in collaboration with the largest prenatal care center in Europe: Harris Birthright Research Center for Fetal Medicine, London and Professor Kypros Nikolaides.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”sxetikamediadikasia”][vc_column_inner][vc_column_text]<\/p>\n

How the results of the Vanadis NIPT test are reported:<\/h2>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”first-text”][vc_column_inner el_class=”first-column” width=”1\/2″][vc_column_text]Low probability (Negative): This means that it is very unlikely that the baby will be affected by Down, Edwards or Patau syndromes.<\/p>\n

Increased probability (Positive): This means that the baby is more likely to be affected by Down, Edwards or Patau syndromes. All increased possible results should be confirmed by an invasive diagnostic test that could be chorionic villus sampling (CVS) or amniocentesis. Confirmation is required in all cases of increased likelihood (positive) as in a very small number of cases the DNA from the placenta may not represent your baby’s DNA.
\n[\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/2″][vc_column_text]Failed test: Very rarely a test could fail for technical or other reasons. In this case a new sample will be required<\/p>\n

Uncertain result: This means that it was not possible to get a clear result. In this case and after consultation with your gynecologist, an invasive test (CVS or amniocentesis) might be required.<\/p>\n

Report sample (to be provided)[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row el_id=”mi-epembatikos”][vc_column][vc_row_inner el_class=”breadcrumbs”][vc_column_inner width=”1\/2″][vc_column_text][\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/2″][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”intro”][vc_column_inner][vc_single_image image=”668″][vc_column_text] Non-Invasive Prenatal Test (NIPT) [\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”description”][vc_column_inner width=”1\/2″][vc_column_text] GENOMEDICA, with the support of PERKIN ELMER, world leader in prenatal testing solutions, has installed and implements in its laboratories the unique Non-Invasive Prenatal Test (NIPT), VANADIS, which covers the wider geographical area of SE and Central Europe and Mediterranean and […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-1604","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\n